Equillium, Inc. (0A4D.L)

1,8200 +0,1200 (+7,06%) In data: 05:54PM BST. Mercato aperto.

Equillium, Inc.

2223 Avenida De La Playa
Suite 105
La Jolla, CA 92037
United States
858 240 1200
https://www.equilliumbio.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 44

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel Mark Bradbury	Executive Chairman	158k	N/D	1961
Mr. Bruce D. Steel C.F.A.	Co-Founder, President, CEO & Director	779,87k	N/D	1966
Ms. Christine Zedelmayer M.B.A., P.M.P.	Senior VP & COO	553,73k	N/D	1970
Dr. Stephen Connelly Ph.D.	Chief Scientific Officer & Director	571,32k	N/D	1982
Mr. Jason A. Keyes	Chief Financial Officer	N/D	N/D	1971
Penny Tom	Senior VP of Finance & Principal Accounting Officer	N/D	N/D	N/D
Mr. Michael Moore	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Dr. Matthew Ritter Ph.D.	Senior Vice President of Corporate Development	N/D	N/D	N/D
Mr. Joel M. Rothman	Chief Development Officer	N/D	N/D	1969
Dr. Maple Fung M.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Governance aziendale

L'ISS Governance QualityScore di Equillium, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.